1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUY
Fresenius SE & Co. KGaAUS flagOther OTC
13.09
USD
+0.09
- -
117.96BMarket Cap
Fresenius SE & Co. KGaA
FSNUY
(Other OTC)

Recent

price

13.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.21
8.36
9.28
9.46
10.73
12.67
13.46
15.26
15.06
15.87
16.24
16.81
9.59
9.35
9.74
10.15
7.96
Revenue per Share
0.62
0.35
0.45
0.47
0.49
0.62
0.71
0.82
0.91
0.84
0.76
0.81
0.61
-0.26
0.21
0.56
0.52
Basic EPS, GAAP
0.6
-0.21
-0.5
-0.68
-0.45
0.66
0.58
-1.88
0.23
-0.3
1.53
0.91
0.9
1.41
0.62
0.48
0.32
Free Cash Flow per Basic Share
0.17
0.19
0.21
0.23
0.27
0.29
0.34
0.42
0.41
0.43
0.47
0.48
0.18
0.24
- -
0.3
- -
Dividend per Share
- -
12.21
14.25
15.17
17.21
20
23.1
24.58
27.66
30.05
30.66
33.95
36.25
33.73
34.7
33.92
34.97
Book Value per Share
- -
-15.71
-16.18
-14.58
-22.08
-22.13
-21.89
-26.62
-24.1
-26.55
-24.21
-24.62
-27.37
2.45
3.61
4.24
5.24
Tangible Book Value per Share
1,945
1,957
2,080
2,148
2,165
2,180
2,190
2,221
2,226
2,231
2,234
2,232
2,245
2,253
2,253
2,253
2,250
Basic Weighted Avg Shares
15,972
16,361
19,290
20,331
23,231
27,626
29,471
33,886
33,530
35,409
36,277
37,520
21,532
21,067
21,954
22,873
17,919
Sales/Revenue/Turnover
15.14
15.67
15.46
14.71
13.4
14.03
14.6
13.47
13.25
13
12.09
11.08
8.42
5.62
9.44
9.54
9.49
Operating Margin (%)
639
674
776
843
937
1,115
1,215
1,437
1,494
2,452
2,715
2,667
1,157
1,400
1,239
1,120
1,131
Depreciation Expense
1,205
690
926
1,011
1,067
1,358
1,560
1,814
2,027
1,883
1,707
1,818
1,372
-594
471
1,264
1,178
Net Income, GAAP
32.53
31.26
27.56
27.79
27.87
29.58
28.06
22.67
20.37
22.57
24.24
22.81
23.48
62.74
31.51
26.6
26.06
Effective Tax Rate (%)
7.54
4.22
4.8
4.97
4.59
4.92
5.29
5.35
6.05
5.32
4.71
4.85
6.37
-2.82
2.15
5.53
6.57
Profit Margin (%)
724
1,163
2,915
1,949
2,924
3,131
2,665
1,939
1,515
1,380
2,659
2,399
4,621
3,190
2,437
2,644
2,543
Working Capital
2,369
7,773
10,300
10,984
13,693
13,607
12,843
16,143
14,040
21,750
22,243
22,383
24,727
13,249
10,805
10,462
9,554
LT Debt
8,844
10,894
13,156
13,732
16,164
18,950
20,849
21,720
25,008
26,580
26,023
29,288
32,218
19,651
20,290
19,767
20,399
Total Equity
11.33
10.48
9.59
8.51
7.79
8.42
8.99
9.31
8.33
7.25
6.27
5.91
2.38
0.92
4.09
4.88
3.97
Return on Invested Capital (%)
15.27
2.72
2.85
2.92
2.92
3.15
2.68
3.32
2.56
2.9
2.19
2.41
1.53
1.48
2.95
4.64
3.55
Return on Capital (%)
26.2
12.62
13.61
12.77
12.17
13.4
13.22
13.78
13.94
11.7
10.12
10.11
6.96
-3.01
2.44
6.54
6.2
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,471
2,367
1,863
LT Borrowings
9,220
8,311
8,326
LT Finance Leases
1,242
1,227
1,228
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
563
563
563
Market Capitalization
6,871
6,274
5,625

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
11,027
12,068
11,612
Cash, Cash Equivalents & STI
1,307
3,949
1,414
Accounts Receivable, Net
3,558
3,962
4,363
Inventories
2,611
2,730
2,773
Total Current Liabilities
8,383
9,537
9,069
Payables & Accruals
- -
- -
- -
ST Debt
1,471
2,367
1,863
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.77%
-3.16%
-2.58%
Free Cash Flow
-145.01%
-12.63%
-22.35%
Net Income, GAAP
-14.58%
-34.45%
168.37%
Sales/Revenue/Turnover
-0.43%
-6.59%
4.19%
Total Cash Common Dividend
- -
- -
24.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,350
5,440
5,315
5,630
21,954
2025
5,706
5,650
- -
6,156
22,873
2026
5,818
5,945
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
-0.16
0.15
- -
0.21
2025
0.1
0.14
- -
- -
0.56
2026
0.19
0.17
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.04
0.25
- -
- -
0.3
2026
- -
- -
- -
- -
- -
Similar Companies
Yatharth Hospital & Trauma Care Services Limited (YATHARTH.BO)
Republic Healthcare Limited (8357.HK)
Universal Health Services, Inc. (UHID)
Ryman Healthcare Limited (RYHTY)
Nutex Health, Inc. (NUTX)
CEDAR.Co.,Ltd. (2435.T)
Business
Fresenius SE & Co. KGaA is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany, founded in 1912. The company operates primarily through its core business segments: Fresenius Kabi, which specializes in biopharmaceuticals, clinical nutrition, MedTech products including infusion systems, intravenously administered generic drugs, and IV fluids; Fresenius Helios, the leading private hospital operator in Europe with extensive inpatient and outpatient services primarily in Germany and Spain; and Fresenius Medical Care, a publicly traded company in which Fresenius holds a significant stake, focusing on dialysis products and services for patients with chronic kidney failure globally. Fresenius Kabi supports critically and chronically ill patients with therapeutic products such as biologic drugs, clinical nutrition including enteral and parenteral nutrition, and infusion therapy products. Fresenius Helios operates more than 110 hospitals and treats over 4 million patients annually. Fresenius Medical Care provides dialysis machines, dialyzers, renal pharmaceuticals, and related medical devices, holding a strong market position especially in the U.S. and Europe. Recent major company changes include the continued strategic transformation under the #FutureFresenius program which focuses on three therapy platforms: (bio)pharma including clinical nutrition, MedTech, and care provision. In 2024-2025, Fresenius has completed significant portfolio optimization including the sale of the Eugin Group, strengthened its biopharma business through partnerships and integration with mAbxience, and launched several new innovative products such as the pediatric parenteral nutrition 3-Chamber-Bag PediSmof. The company has expanded its digital health and advanced therapy investments and is pursuing growth through outpatient sector expansions by linking medical care centers more closely to hospitals. Fresenius also secured a €400 million loan from the European Investment Bank to support R&D innovation and capacity expansion. Financially, Fresenius reported strong organic growth with Q3 2025 revenues at €5.477 billion and raised EBIT growth guidance, driven by consistent performance in Fresenius Kabi and Helios despite challenging macroeconomic conditions. Fresenius operates in over 60 countries with over 50 production sites worldwide, targeting healthcare providers, hospitals, and chronically ill patients. The company is positioned to leverage trends like aging populations and healthcare expansion globally. Its latest strategic focus involves simplifying the group structure, optimizing financial management, and creating sustainable value through innovative, accessible, and affordable healthcare products and services. This description integrates the company's detailed product offerings, geographic reach, strategic initiatives, and recent operational and financial developments reflecting its position as a leading global healthcare provider.

Company News

Company News APIChatGPT

  • zacks.com

    All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy

  • zacks.com

    Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?

  • zacks.com

    Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    Fresenius establishes venture fund of more than €200 million to drive healthcare innovation

  • zacks.com

    Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?

  • zacks.com

    Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?

  • zacks.com

    Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • defenseworld.net

    Fresenius SE & Co. (OTCMKTS:FSNUY) vs. U.S. Physical Therapy (NYSE:USPH) Head to Head Review

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript

  • defenseworld.net

    Financial Review: Fresenius SE & Co. (OTCMKTS:FSNUY) vs. DaVita (NYSE:DVA)

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Fresenius: Healthy Portfolio Add

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Fresenius: Turnaround For Company, Stock Price

  • seekingalpha.com

    Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript